Q Financial Update November 6, 2018 NASDAQ:FPRX
|
|
- Diana McDowell
- 5 years ago
- Views:
Transcription
1 Q Financial Update November 6, 2018 NASDAQ:FPRX
2 2 Forward-Looking Statements Disclaimer Forward-looking statements contained in this presentation include statements regarding (i) the timing of initiation, progress and scope of clinical trials for Five Prime s product candidates; (ii) the potential use of our Five Prime s product candidates, including in combination with other products, to treat certain patients; (iii) the extent of protein overexpression in certain patient populations and the number of potential patients eligible for treatment with our products; (iv) the prevalence and incidence of certain diseases; (iv) the timing of the presentation of data for Five Prime s product candidates; (vi) the date David V. Smith will join Five Prime as Executive Vice President and Chief Financial Officer; (vii) Five Prime s full-year 2018 net cash used in operating activities; and (viii) the amount of Five Prime s cash, cash equivalents and marketable securities at the end of Many factors may cause differences between current expectations and actual results including unexpected safety or efficacy data observed during research, preclinical or clinical studies, changes in expected or existing competition, changes in the regulatory, pricing or reimbursement environment, and unexpected litigation or other disputes. Other factors that may cause actual results to differ from those expressed or implied in the forwardlooking statements in this press release are discussed in Five Prime s filings with the U.S. Securities and Exchange Commission, including the Risk Factors contained therein. Except as required by law, Five Prime assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.
3 Five Prime Highlights Bemarituzumab (FGFR2b antibody; FPA144) o o Initiated patient dosing in the randomized, controlled Phase 3 FIGHT trial of bemarituzumab with chemotherapy in front-line gastric and GEJ cancer. Present data from the Phase 1 safety lead-in of the FIGHT trial at ASCO GI conference. Cabiralizumab (CSF1R antibody; FPA008) o o o BMS is enrolling patients in a randomized Phase 2 trial evaluating cabiralizumab + OPDIVO as a 2 nd -line treatment in ~160 patients with pancreatic cancer. Stand Up To Cancer and BMS are supporting a randomized Phase 2 front-line maintenance trial (GemCaN) to test if cabiralizumab + OPDIVO can provide prolonged disease control in patients with advanced pancreatic cancer compared to gemcitabine alone. Apexigen and BMS are supporting a Phase 1/1b trial evaluating APX005M (anti-cd40) + cabiralizumab + OPDIVO in patients with melanoma, non-small cell lung cancer or renal cell carcinoma whose disease has progressed on a prior regimen containing a PD-1 or PD-L1 inhibitor without intervening therapy. FPA150 (B7-H4 antibody) o o o Initiated dosing in an exploratory basket cohort of patients with tumors that overexpress B7-H4 to investigate FPA150 monotherapy at doses that have shown efficacy in preclinical models. Phase 1a dose escalation in solid tumors is ongoing; dosing in seventh of eight expected cohorts. Phase 1b dose expansion in patients whose tumors overexpress B7-H4 (HR+/HER2- and triple negative breast cancers, ovarian cancer and endometrial cancer) will follow completion of Phase 1a. o Anticipate presenting Phase 1 data at a medical conference in FPT155 (CD80-Fc) o Opened enrollment in the dose escalation portion of a Phase 1a/1b trial in Australia. BMS (TIM-3 antibody) o BMS Phase 1/2 trial is testing BMS both as a single agent and in combination with OPDIVO. o BMS to present preclinical poster at SITC conference. 3
4 4 Oncology-Focused Pipeline with Multiple Clinical Candidates Program Collaborator Bemarituzumab (FPA144) FGFR2b ANTIBODY Cabiralizumab (FPA008) CSF-1R ANTIBODY FIGHT trial (with chemo) in gastric/gej cancer 2L pancreatic cancer trial (with OPDIVO and chemo) Phase 2 1L maintenance Stand Up to Cancer and BMS supported trial (with OPDIVO) Phase 2 Phase 3 Multiple tumor settings (with OPDIVO) Apexigen & BMS supported trial for APX005M (anti-cd40) and cabira and OPDIVO Phase 1 Phase 1 BMS TIM-3 ANTIBODY Phase 1/2 trial in multiple tumor settings Phase 1 FPA150 B7-H4 ANTIBODY Multiple tumor settings Phase 1a FPT155 CD80-Fc FUSION Multiple tumor settings Phase 1a I-O antibodies Multiple tumor settings Pre-IND Novel I-O biologics Multiple tumor settings Lead Generation
5 Attractive Commercial Opportunity for Bemarituzumab in Front-Line Treatment of FGFR2b+ Gastric and GEJ Cancer 5 Estimated Addressable Metastatic Gastric and GEJ Adenocarcinoma Patients 1 US EU Japan/Korea China 1 st line patients 28, , , ,000 Treatment eligible (10% FGFR2b+) Patients treated with systemic therapy 2,840 15,300 13,430 47,400 2,050 11,020 9,670 34,130 Global pricing for recently launched biologics range ~$6,500 to >$14,000/month 1 Median PFS of FOLFOX alone in front-line gastric cancer treatment: 6-7 months 2 Median OS of FOLFOX alone in front-line gastric cancer treatment: months 2 Unmet need: FGFR2b+ patients have significantly reduced survival 3 1) Internal estimates based on population, published incidence and recurrence rates and estimated treatment rates, CancerMPact Kantar Health, Accessed October ) Yoon et al. J Clin Oncol Shah et al. JAMA Oncol Al-Batran SE et al. J Clin Oncol ) Jung et al Hattori et al
6 Attractive Market Opportunity for Cabira: Unresectable or Metastatic Pancreatic Cancer in Major Markets 6 Incidence (2016) 1 US EU5* Japan First-line 45,950 52,130 32,240 Second-line 22,827 26,049 15,618 Sources: 1 - Decision Resources Group; Pancreatic Cancer Epidemiology Overview, August * - EU5 = France, Germany, Italy, Spain, UK
7 FPA150: Opportunity to Address Large Patient Populations with High Unmet Medical Need 7 Late-line Treatment Estimated Eligible Population 1 US EU5 Japan TNBC 3L+ 5,170 5,230 2,000 HR+/HER2- Breast Hormone-refractory and 3L chemo+ Ovarian 2L+ platinum-resistant Endometrial 2L+ Estimated Addressable Patients and Unmet Need 45,800 49,560 14,200 10,740 10,970 3,730 Late-line data not available Historical mpfs 2 < 4 months Potential to expand to earlier lines of therapy in combination with standard of care (e.g., PD-(L)1 therapy, chemotherapy, PARP inhibitors) 1 Decision Resources Group 2018, 2 Twelves C, Breast Cancer: Basic and Clinical Research 2016, 3 Mutch DG, J Clin Oncol 2007, 4 Aghajanian C, J Clin Oncol 2011, 5 Powels T, Lancet 2018
8 Bemarituzumab (FPA144) Was Designed to Recruit Tumor-Killing NK Cells into the Tumor Microenvironment and Block Growth Factor Ligands 8 Natural Killer Cell Enhanced ADCC to increase NK cell recruitment Bema FGFR2b FGF7, 10, 22 Specific to FGFR2b splice variant; blocks growth factor ligands Tumor Cell
9 FIGHT Phase 3 Trial of Bemarituzumab in Front-Line FGFR2b+ Gastric and GEJ Cancer 9 Randomized Phase 3 ~550 patients Initiated September 2018 Bema + mfolfox6 vs Placebo + mfolfox6 Study Endpoints OS PFS ORR FGFR2b overexpression and FGFR2 gene amplification associated with worse prognosis ~10% of gastric and GEJ cancer patients expected to be biomarker-positive Select patients by IHC (tumor sample) or ctdna (blood-based) tests
10 Cabiralizumab, a Product of the Five Prime Platform, Blocks Survival of Macrophages 10 Cabiralizumab (FPA008) is an antibody to CSF-1R CSF-1 IL-34 Five Prime discovered IL-34, one of the two ligands for CSF-1R that cabiralizumab (FPA008) blocks
11 Durable Responses Observed Without Chemo in Late-Line Pancreatic Cancer* Percent change in tumor burden (SLD) from baseline 11 Best change in tumor burden over time in efficacy-evaluable patients treated with cabiralizumab 4 mg/kg + nivolumab 3 mg/kg (n=31) Progressive disease Treated beyond progressive disease Partial response Day Efficacy & Safety: Durable clinical benefit observed Confirmed ORR = 13% DCR = 16% Disease control: 5 to 9+ months Heavily pretreated population (average 3 prior therapies) All responders had microsatellite stable tumors (do not respond to PD1/L1 therapy) No new or additive safety signals identified Whole exome sequencing analysis demonstrated that nearly all patients had low TMB Days * SITC, November 2017 Wainberg Z, et al.
12 BMS-Sponsored Randomized, Open-Label Phase 2 Trial of Cabiralizumab/OPDIVO in 2 nd -Line Pancreatic Cancer (NCT ) 12 Prior Line: Gemcitabine-Based Chemotherapy Trial Arms (2 nd -Line) Arm A: Chemotherapy alone Gemcitabine/Abraxane or 5-FU/leucovorin/Onivyde Arm B: Cabiralizumab + OPDIVO N ~160 patients Study Objectives Progression free survival (primary) Objective response rate and duration Prior Line: 5-Fluorouracil-Based Chemotherapy Arm C: Cabiralizumab + OPDIVO combined with gemcitabine + Abraxane Arm D: Cabiralizumab + OPDIVO combined with oxaliplatin/5-fu/leucovorin Overall survival rate Safety PK First patient dosed January 2018 Study will generate data that could support a front-line or second-line pivotal study
13 13 FPA150 Has Two Mechanisms: Block the Checkpoint and Enhance ADCC Enhanced NK-mediated cell killing (ADCC) FPA150 B7-H4 T Cell B7-H4 Tumor Cell B7-H4 FPA150 Blocks B7-H4 checkpoint activity
14 B7-H4 is Expressed in Multiple Solid Tumors Not Well Served by Checkpoint Inhibitors 14 Expression Levels N e g a t i v e M o d e r a t e - H i ( ~ 6 0 % ) N e g a t i v e M o d e r a t e - H i ( ~ 5 0 % ) N e g a t i v e M o d e r a t e - H i ( ~ 5 0 % ) L o w L o w L o w Breast cancer T N B C Ovarian O v a r i a n cancerc a n c e r Endometrial E n d o m e t r i a l c a cancer n c e r Very little expression on normal cells/tissue
15 FPA150: Phase 1a/1b Clinical Trial to Look for Monotherapy Activity Against B7-H4 Overexpressing Tumors 15 PHASE 1a Dose escalation Any Solid Tumor Initiated March 2018 Exploratory cohort Basket B7-H4+ Tumors Initiated Oct PHASE 1b Expansion; B7-H4+ tumors HR+/HER2- Breast Cancer Triple Negative Breast Cancer Ovarian Cancer Study Objectives Safety Objective response rate and duration Survival Baseline and on-treatment biopsies Endometrial Cancer IHC assay to select patients with B7-H4 expressing tumors in exploratory cohort and Phase 1b Evaluating I-O and chemo combination strategies Additional Cohorts TBD
16 FPT155: First-In-Class CD80-Fc Fusion Protein Engineered for Monotherapy Efficacy by Activating T Cells Through Multiple Pathways 16 Normal T cell activation via CD80 Antigen presenting cell MHC TCR T cell (+) signal FPT155 uses the binding interactions of soluble CD80 to: Directly engage CD28 to enhance its co-stimulatory activity (without super agonism) Block CTLA-4 from competing for endogenous CD80, allowing CD28 signaling to prevail in T cell activation CD80 CD28 CD80 extracellular domain CD80 is a co-stimulatory molecule expressed on antigen presenting cells Human IgG1 Fc
17 T u m o r V o lu m e (M e a n m m 3 S D ) 17 Single Agent mfpt155 Can Induce Tumor Regressions at Low Doses CT26 Tumor Growth Ig G 2 a 0.9 m g /k g m F P T m g /k g (s in g l m F P T m g /k g (s in g l m F P T m g /k g (s in g l migg2 control m F P T m g /k g (s in g l 0.1 mg/kg mmfpt155 F P T One m g /k g (3 d o s 0.2 mg/kg mfpt155 administration 0.6 mg/kg m mfpt155 F P T m g /k g (3 d o s 0.9 mg/kg mmfpt155 F P T m g /k g (3 d o s 0.1 mg/kg mfpt155 Three 0.2 mg/kg mfpt155 administrations 0.3 mg/kg mfpt D a y s p o s t-in o c u la tio n Murine FPT155 (mfpt155) demonstrates monotherapy anti-tumor activity in MC38, EMT6, 4T1, and B16-F10 models
18 mfpt155 Has Synergistic Activity in Combination with anti-pd1 in Large Tumors that are Insensitive to Anti-PD1 18 migg2a CT26 Tumor Growth mfpt155 5/15 rejections anti-pd1 Combination 9/15 rejections
19 19 IND Engine: Unique Platform Generating Novel Therapeutics Comprehensive Libraries of Extracellular Proteins Proprietary Screens Protein Therapeutics Secreted Factors In Clinical Development bemarituzumab (anti-fgfr2b ) Cell-based Screens Antibodies cabiralizumab (anti-csf-1r) Cell Surface Receptors/Ligands In Vivo Screens Soluble Receptors Ligand Traps FPA150 (anti-b7h4) BMS (anti-tim-3) Soluble Extracellular Domains Receptor-Ligand Matching FPT155 (CD80-Fc Fusion)
20 20 Cash and Shares Outstanding Cash, cash equivalents & marketable securities Shares outstanding Estimated cash, cash equivalents & marketable securities, EOY 2018 FY 2018 estimated net cash used in operating activities $321.6 million as of Sept. 30, million as of Sept. 30, 2018 ~ $265 million < $135 million
21 Summary of Financial Results (In Millions Except Per Share Amounts) 21 3Q18 3Q17 Revenue $5.8 $8.3 R&D Expenses $44.7 $42.7 G&A Expenses $9.8 $9.7 Net Loss ($47.2) ($43.3) EPS Basic & Diluted ($1.37) ($1.54)
22 Five Prime News Flow and Milestones Bemarituzumab (FPA144) GASTRIC/GEJ CANCER Cleared Phase 1 safety lead-in to FIGHT chemo combo trial Initiated randomized, global Phase 3 FIGHT trial Present Phase 1 FIGHT trial safety lead-in data at the ASCO GI conference FPA150 (B7-H4 Antibody) Initiated exploratory cohort of FPA150 monotherapy in patients with tumors that overexpress B7-H4 Complete Phase 1a dose escalation, select a dose and initiate Phase 1b expansion Present Phase 1 data at medical conference in 2019 Cabiralizumab PANCREATIC CANCER BMS completes enrollment in randomized Phase 2 trial (2 nd -line pancreatic) combo with OPDIVO + chemo Stand Up To Cancer & BMS initiated randomized Ph 2 front-line maintenance pancreatic trial (GemCaN) FPT155 (CD80-Fc Fusion Protein) Opened enrollment in Phase 1a dose escalation portion of Phase 1 trial in Australia BMS (TIM-3 Antibody) BMS advances trial to Phase 2 BMS presents preclinical poster at SITC 22
23 Thank you NASDAQ:FPRX
Corporate Overview. September 2018 NASDAQ:FPRX
Corporate Overview September 2018 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform
More informationLeerink Immuno-Oncology Roundtable Conference
Leerink Immuno-Oncology Roundtable Conference September 28, 2017 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private
More informationCorporate Overview. June 2018 NASDAQ:FPRX
Corporate Overview June 2018 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of
More informationCorporate Overview. March 2018 NASDAQ:FPRX
Corporate Overview March 2018 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act
More informationCorporate Overview. June 2017 NASDAQ:FPRX
Corporate Overview June 2017 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of
More informationFive Prime Therapeutics, Inc. Corporate Overview
Five Prime Therapeutics, Inc. Corporate Overview June 2015 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities
More informationInvestor Webcast: Initial Data from Phase 1a/1b Trial of Cabiralizumab/OPDIVO and Early Efficacy Signal in Pancreatic Cancer.
Investor Webcast: Initial Data from Phase 1a/1b Trial of Cabiralizumab/OPDIVO and Early Efficacy Signal in Pancreatic Cancer November 8, 2017 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation
More informationMore cancer patients are being treated with immunotherapy, but
Bristol-Myers Squibb and Five Prime Present Phase 1a/1b Data Evaluating Cabiralizumab (anti-csf-1 receptor antibody) with Opdivo (nivolumab) in Patients with Advanced Solid Tumors PRINCETON, N.J. & SOUTH
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 3Q 2018 EARNINGS PRESENTATION NOVEMBER 2018 1 Forward-looking statements disclosure This presentation
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 4Q 2016 EARNINGS PRESENTATION MARCH 2017 1 Forward-looking statements disclosure This presentation contains
More informationDetermined to realize a future in which people with cancer live longer and better than ever before Q Conference Call
Reimagining Cancer Treatment Determined to realize a future in which people with cancer live longer and better than ever before Q1 2016 Conference Call 1 Forward-Looking Statements Disclosure This presentation
More informationWells Fargo Healthcare Conference September 6, 2018
Wells Fargo Healthcare Conference September 6, 2018 Safe Harbor Statement To the extent that statements contained in this presentation are not descriptions of historical facts regarding TESARO, they are
More information33 rd Annual J.P. Morgan Healthcare Conference. January 2015
33 rd Annual J.P. Morgan Healthcare Conference January 2015 Forward-looking Statements This presentation contains forward-looking statements, which express the current beliefs and expectations of management.
More informationDetermined to realize a future in which people with cancer live longer and better than ever before CORPORATE PRESENTATION SEPTEMBER 2017
Determined to realize a future in which people with cancer live longer and better than ever before CORPORATE PRESENTATION SEPTEMBER 2017 1 Forward-looking statements disclosure This presentation contains
More informationThird Quarter 2015 Earnings Call. November 9, 2015
Third Quarter 2015 Earnings Call November 9, 2015 Forward-Looking Statements All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements
More informationImmune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment
Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment 1 Introductions Peter Langecker, MD, PhD Executive Medical Director, Global Oncology Clinipace Worldwide Mark Shapiro Vice President
More informationArQule Jefferies Global Healthcare Conference June 2015
ArQule Jefferies Global Healthcare Conference June 2015 1 ArQule Corporate Update Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning
More informationCORPORATE PRESENTATION
CORPORATE PRESENTATION June 2017 FORWARD LOOKING SAFE HARBOR STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
More informationNovel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates
Novel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates Christopher Turner, MD Vice President, Clinical Science 04 November 2016 Uveal Melanoma Celldex Pipeline CANDIDATE INDICATION Preclinical
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 1Q 2018 EARNINGS PRESENTATION MAY 2018 1 Forward-looking statements disclosure This presentation contains
More informationLION. Corporate Presentation June 2016 BIOTECHNOLOGIES. Leadership & Innovation in Oncology
LION BIOTECHNOLOGIES Leadership & Innovation in Oncology Corporate Presentation June 2016 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private
More information2016 Year-End Results and Conference Call. March 14, 2017
2016 Year-End Results and Conference Call March 14, 2017 Forward Looking Statement This communication contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform
More informationCiti s 13 th Annual Biotech Conference September 5, 2018
Citi s 13 th Annual Biotech Conference September 5, 2018 Safe Harbor Statement To the extent that statements contained in this presentation are not descriptions of historical facts regarding TESARO, they
More informationBusiness Update & Financial Results for Q1 2018
Business Update & Financial Results for Q1 2018 May 15, 2018 Disclaimer The statements made in this presentation may include forward-looking statements regarding the future operations of ERYTECH Pharma
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 4Q 2017 EARNINGS PRESENTATION MARCH 2018 1 Forward-looking statements disclosure This presentation contains
More informationDetermined to realize a future in which people with cancer live longer and better than ever before 4Q18 EARNINGS PRESENTATION MARCH 2019
Determined to realize a future in which people with cancer live longer and better than ever before 4Q18 EARNINGS PRESENTATION MARCH 2019 Forward-looking statements disclosure This presentation contains
More informationSyndax Announces Updated Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA (pembrolizumab)
Syndax Announces Updated Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA (pembrolizumab) Ongoing ENCORE 601 biomarker analyses suggest enhanced clinical benefit in subpopulation
More informationNewLink Genetics Corporation
Cantor Fitzgerald 2018 Global Healthcare Conference NewLink Genetics Corporation NASDAQ: NLNK October 3, 2018 Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking
More informationDetermined to realize a future in which people with cancer live longer and better than ever before CORPORATE PRESENTATION JUNE 2017
Determined to realize a future in which people with cancer live longer and better than ever before CORPORATE PRESENTATION JUNE 2017 1 Forward-looking statements disclosure This presentation contains forward-looking
More informationBAVARIAN NORDIC BIO DEUTSCHLAND PRESENTATION OCTOBER 2014 CSE/OMX:BAVA, OTC:BVNRY
BAVARIAN NORDIC BIO DEUTSCHLAND PRESENTATION OCTOBER 2014 CSE/OMX:BAVA, OTC:BVNRY This presentation includes "forward-looking statements" that involve risks, uncertainties and other factors, many of which
More informationIdentification of novel immune regulators of tumor growth using highthroughput
Identification of novel immune regulators of tumor growth using highthroughput screening in vivo Tom Brennan 1 Five Prime s Unique Platform Tests Nearly Every Extracellular Protein to Identify Protein
More informationNektar Investor & Analyst Call. Nektar & z Bristol-Myers Squibb Collaboration. February 14, 2018
Nektar Investor & Analyst Call Nektar & z Bristol-Myers Squibb Collaboration February 14, 2018 This presentation includes forward-looking statements regarding Nektar s proprietary drug candidates, the
More informationOncoSec Provides 2018 Business Outlook
January 3, 2018 OncoSec Provides 2018 Business Outlook Complete stage 1 enrollment of PISCES/KEYNOTE-695 clinical trial of ImmunoPulse IL-12 in combination with KEYTRUDA (pembrolizumab) Present preliminary
More informationNewLink Genetics Corporation Provides Operational Update and Reports Second Quarter 2015 Financial Results
July 31, 2015 NewLink Genetics Corporation Provides Operational Update and Reports Second Quarter 2015 Financial Results -Management to Host Conference Call Today at 8:30 a.m. ET- AMES, Iowa, July 31,
More informationReimagining Cancer Treatment. Determined to realize a future in which people with cancer live longer and better than ever before
Reimagining Cancer Treatment Determined to realize a future in which people with cancer live longer and better than ever before Cantor Fitzgerald 2nd Annual Healthcare Conference July 13, 2016 Forward-Looking
More informationCorporate Overview. July 2016 NASDAQ: CYTR
Corporate Overview July 2016 NASDAQ: CYTR CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES ASSOCIATED WITH A DEVELOPMENT-STAGE
More informationFORWARD II PROGRAM UPDATE
FORWARD II PROGRAM UPDATE NASDAQ: IMGN May 17, 2018 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements based on management's current expectations. These statements include,
More informationADAPTIMMUNE INVESTOR PRESENTATION. August 2016
ADAPTIMMUNE INVESTOR PRESENTATION August 2016 DISCLAIMER This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA),
More informationInvestor Call. May 19, Nasdaq: IMGN
Investor Call May 19, 2017 Nasdaq: IMGN Forward-Looking Statements This presentation includes forward-looking statements based on management's current expectations. These statements include, but are not
More informationINTERIM RESULTS AS OF JUNE 30, 2014 CSE/OMX:BAVA, OTC:BVNRY
INTERIM RESULTS AS OF JUNE 30, 2014 Q2 AUGUST 28, 2014 CSE/OMX:BAVA, OTC:BVNRY FINANCIAL HIGHLIGHTS 2.6 million doses IMVAMUNE delivered to the SNS during H1 (0.9 million in Q2) Increased contribution
More informationCorporate Presentation
Corporate Presentation Leerink Global Healthcare Conference February 14 th -15 th, 2018 C O N F I D E N T I A L a n d P R O P R I E T A R Y Forward Looking Statements / Safe Harbor This presentation contains
More informationBuilding a Premier Oncology Biotech
Corporate Deck Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO November 2018 Forward-Looking Statements All of the statements in this presentation that are not statements of historical
More informationCorporate Presentation: Jefferies Global Healthcare Conference June 7, 2018
Corporate Presentation: Jefferies Global Healthcare Conference June 7, 2018 2018 CytomX Therapeutics, Inc. 1 Forward Looking Statements Special Note Regarding Forward-Looking Statements This presentation
More informationDivision of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
Antitumor Activity and Safety of FPA144, an ADCCenhanced, FGFR2b Isoform-Selective Monoclonal Antibody, in Patients with FGFR2b + Gastric Cancer and Advanced Solid Tumors Jeeyun Lee 1, Johanna Bendell
More informationArQule CorporateUpdate
ArQule April 2015 1 ArQule CorporateUpdate Safe Harbor This presentation and other statements by ArQule may contain forwardlooking statements within the meaning of the Private Securities Litigation Reform
More informationBank of America Merrill Lynch 2018 Health Care Conference. Reinventing Therapeutic Antibodies for the Treatment of Cancer
Bank of America Merrill Lynch 2018 Health Care Conference Reinventing Therapeutic Antibodies for the Treatment of Cancer May 17, 2018 1 Forward Looking Statements Special Note Regarding Forward-Looking
More informationJuly, ArQule, Inc.
July, 2012 Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to clinical
More informationBuilding a Premier Oncology Biotech
Wells Fargo Securities Healthcare Conference Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO September 2018 Forward-Looking Statements All of the statements in this presentation
More informationTARGET A BETTER NOW FORWARD-LOOKING STATEMENTS NASDAQ: IMGN. Current as of January 2018
NASDAQ: IMGN TARGET A BETTER NOW Current as of January 2018 FORWARD-LOOKING STATEMENTS This presentation includes forward looking statements based on management's current expectations. These statements
More informationCorporate Presentation October 2018 Nasdaq: ADXS
Innovations in Immuno-Oncology Corporate Presentation October 2018 Nasdaq: ADXS Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements
More informationNational Bank 8th Annual Quebec Conference TSX: IMV. May 30, IMV Inc. All rights reserved.
National Bank 8th Annual Quebec Conference TSX: IMV May 30, 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV Inc.
More informationDawson James Conference
Dawson James Conference October 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV s current expectations regarding
More informationJune IMMUNE DESIGN The in vivo generation of cytotoxic CD8 T cells (CTLs)
June 2015 IMMUNE DESIGN The in vivo generation of cytotoxic CD8 T cells (CTLs) 1 Forward-looking Statements This presentation contains forward-looking statements with respect to, among other things, our
More informationIMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics. Jefferies 2014 Global Healthcare Conference Cynthia L. Sullivan, President and CEO
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases Jefferies 2014 Global Healthcare Conference Cynthia L. Sullivan, President and CEO Forward-Looking Statements This presentation,
More informationLeading the Next Wave of Biotech Breakthroughs
Leading the Next Wave of Biotech Breakthroughs Corporate Extensive corporate assets Platforms Pipeline Partnerships Building a sustainable global business Platform licenses represent a source of non-dilutive
More informationRexahn Pharmaceuticals Overview
Rexahn Pharmaceuticals Overview May 2018 Safe Harbor Statement The statements that follow (including projections and business trends) are forward-looking statements. Rexahn s actual results may differ
More informationProstate Cancer Panel. June 2018
Prostate Cancer Panel June 2018 Forward Looking Statements Certain of the statements made in this presentation are forward looking, such as those, among others, relating to future spending, future cash
More informationIdera Pharmaceuticals
Idera Pharmaceuticals ILLUMINATE-204 Clinical Data Update December 2018 Forward Looking Statements and Other Important Cautions This presentation contains forward-looking statements within the meaning
More informationNewLink Genetics Corporation
Stifel Healthcare Conference Presentation NewLink Genetics Corporation NASDAQ: NLNK November 13, 2018 Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements
More informationIMMUNOMEDICS, INC. November Advanced Antibody-Based Therapeutics. Oncology Autoimmune Diseases
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases November 2017 Forward-Looking Statements This presentation, in addition to historical information, contains certain
More informationInvestor Meetings October 2018
Investor Meetings October 2018 Safe Harbor Statement To the extent that statements contained in this presentation are not descriptions of historical facts regarding TESARO, they are forward-looking statements
More informationIMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases Rodman & Renshaw 19 th Annual Global Investment Conference Michael R. Garone, Principal Executive Officer and CFO Forward-Looking
More informationREWRITING CANCER TREATMENT THROUGH EPIGENETIC MEDICINES
REWRITING CANCER TREATMENT THROUGH EPIGENETIC MEDICINES May 18, 2017 Molecularly Defined Solid Tumor Program Update FORWARD-LOOKING STATEMENTS Any statements in this press release about future expectations,
More informationBuilding a Premier Oncology Biotech
Building a Premier Oncology Biotech August 208 Forward-Looking Statements All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements within
More informationInducing Tumor-Specific Ischemic Necrosis to Enhance the Efficacy of Checkpoint Inhibitors and Chemotherapy
Inducing Tumor-Specific Ischemic Necrosis to Enhance the Efficacy of Checkpoint Inhibitors and Chemotherapy Company Overview, September 2018 Safe Harbor Statement This presentation contains forward-looking
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer January 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward looking statements. Rexahn's actual results
More informationCorporate Overview May 8, 2014
0 Corporate Overview May 8, 2014 NASDAQ: CRIS Forward Looking Statements This presentation contains statements about Curis future expectations, plans and prospects that constitute forward-looking statements
More informationImmuno-Oncology Clinical Trials Update: Checkpoint Inhibitors Others (not Anti-PD-L1/PD-1) Issue 4 January 2017
Delivering a Competitive Intelligence Advantage Immuno-Oncology Clinical Trials Update: Checkpoint Inhibitors Others (not Anti-PD-L1/PD-1) Issue 4 January 2017 Immuno-Oncology CLINICAL TRIALS UPDATE The
More informationMerck ASCO 2015 Investor Briefing
Merck ASCO 2015 Investor Briefing Forward-Looking Statement This presentation includes forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation
More informationESMO 2017, Madrid, Spain Dr. Loredana Vecchione Charite Comprehensive Cancer Center, Berlin HIGHLIGHTS ON CANCERS OF THE UPPER GI TRACT
ESMO 2017, Madrid, Spain Dr. Loredana Vecchione Charite Comprehensive Cancer Center, Berlin HIGHLIGHTS ON CANCERS OF THE UPPER GI TRACT DOCETAXEL, OXALIPLATIN AND FLUOROURACIL/LEUCOVORIN (FLOT) FOR RESECTABLE
More informationCONSIDERATIONS IN DEVELOPMENT OF PEMBROLIZUMAB IN MSI-H CANCERS
CONSIDERATIONS IN DEVELOPMENT OF PEMBROLIZUMAB IN MSI-H CANCERS December 2017 Christine K. Gause, Ph.D Executive Director, Biostatistics. 2 Microsatellite Instability-High Cancer - USPI KEYTRUDA is indicated
More informationASCO 2018 Investor Meeting
ASCO 2018 Investor Meeting June 4, 2018 1 Forward-Looking Information This presentation contains statements about the Company s future plans and prospects that constitute forward-looking statements for
More informationThird Quarter 2018 Financial Results. November 1, 2018
Third Quarter 2018 Financial Results November 1, 2018 Agios Conference Call Participants Prepared Remarks Introduction RENEE LECK, Associate Director, Investor Relations Business Highlights & 2018 Key
More informationCorporate Presentation March 2016
Corporate Presentation March 2016 Forward Looking Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
More informationVAL-083: Validated DNA-targeting Agent for Underserved Cancer Patients. September 2018
VAL-083: Validated DNA-targeting Agent for Underserved Cancer Patients September 2018 Forward-Looking Statements Any statements contained in this presentation that do not describe historical facts may
More informationFrédéric Triebel MD, PhD World Immunotherapy Congress Basel, October 30, 2018
Two ACTive immunotherapies in melanoma (TACTI-mel): results of a phase I trial combining a soluble LAG-3 receptor (Eftilagimod Alpha) with Pembrolizumab Frédéric Triebel MD, PhD World Immunotherapy Congress
More informationFull Year 2017 Financial Results. February 14, 2018
Full Year 2017 Financial Results February 14, 2018 Agios Conference Call Participants Prepared Remarks Introduction KENDRA ADAMS, Sr. Director, Investor Relations 2018 Vision & Key Milestones DAVID SCHENKEIN,
More informationCowen Annual Healthcare Conference. March 2018
Cowen Annual Healthcare Conference March 2018 Forward Looking Statements Certain of the statements made in this presentation are forward looking, such as those, among others, relating to future spending,
More informationTargeting the genetic and immunological drivers of cancer
NASDAQ: MRTX Targeting the genetic and immunological drivers of cancer Corporate Presentation April 2019 1 Safe Harbor Statement Certain statements contained in this presentation, other than statements
More informationBuilding a Fully Integrated Biopharmaceutical Company. June 2014
Building a Fully Integrated Biopharmaceutical Company June 2014 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer March 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward-looking statements. Rexahn's actual results may
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before CORPORATE PRESENTATION JULY 2018 1 Forward-looking statements disclosure This presentation contains forward-looking
More informationClovis Oncology Announces First Quarter 2017 Operating Results. May 3, :06 PM ET
Clovis Oncology Announces First Quarter 2017 Operating Results May 3, 2017 4:06 PM ET Strong Q1 launch quarter for Rubraca (rucaparib) in U.S. with $7M reported in net sales Clovis notified that ARIEL3
More informationCorporate Overview. February 2018 NASDAQ: CYTR
Corporate Overview February 2018 NASDAQ: CYTR CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES. ACTUAL RESULTS COULD DIFFER
More informationTargeting the Tumor Locally
Targeting the Tumor Locally Cautionary Note Regarding Forward-Looking Statements To the extent statements contained in the following presentations are not descriptions of historical facts regarding OncoSec
More informationArray BioPharma Second Quarter of F2018 Update FEBRUARY 6, 2018
Array BioPharma Second Quarter of F2018 Update FEBRUARY 6, 2018 SAFE HARBOR STATEMENT Forward-looking statements made in the course of this presentation are made pursuant to the safe harbor provisions
More informationThe Next Generation of Immunotherapy Platforms. 36 th Annual J.P. Morgan Healthcare Conference January 2018
The Next Generation of Immunotherapy Platforms 36 th Annual J.P. Morgan Healthcare Conference January 2018 Forward-Looking Statements This presentation contains certain forward-looking information about
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer June 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward looking statements. Rexahn's actual results may
More informationAravive Corporate Presentation October 2018
Aravive Corporate Presentation October 2018 Important Information Forward-Looking Statements This presentation contains forward-looking statements that may discuss Aravive s plans, goals, intentions and
More informationArming the patient s immune system to fight cancer
Arming the patient s immune system to fight cancer Redeye - Fight Cancer Seminar 10 th March 2017 Øystein Soug, CEO Important notice and disclaimer This report contains certain forward-looking statements
More informationCorporate Presentation November Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers
Corporate Presentation November 2015 Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers Forward-looking statements / safe harbor This presentation and the accompanying oral commentary
More informationNewLink Genetics Corporation
Cantor Fitzgerald Global Healthcare Conference NewLink Genetics Corporation NASDAQ: NLNK September 25, 2017 Forward-Looking Disclaimer This presentation contains forward-looking statements of NewLink that
More informationMERCK ONCOLOGY OVERVIEW ASCO 2018 JUNE 4, 2018
MERCK ONCOLOGY OVERVIEW ASCO 218 JUNE 4, 218 Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA This presentation of Merck & Co., Inc., Kenilworth, N.J., USA (the company ) includes forward
More informationInarigivir ACHIEVE Trial Results and HBV Clinical Program Update. August 2, 2018
Inarigivir ACHIEVE Trial Results and HBV Clinical Program Update August 2, 2018 FORWARD LOOKING STATEMENT This presentation includes forward-looking statements within the meaning of the Private Securities
More informationCorporate Overview. May 2017 NASDAQ: CYTR
Corporate Overview May 2017 NASDAQ: CYTR CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES. ACTUAL RESULTS COULD DIFFER MATERIALLY
More informationPTAC meeting held on 5 & 6 May (minutes for web publishing)
PTAC meeting held on 5 & 6 May 2016 (minutes for web publishing) PTAC minutes are published in accordance with the Terms of Reference for the Pharmacology and Therapeutics Advisory Committee (PTAC) and
More informationNOVITA IN TEMA DI CARCINOMA GASTRICO ROSA BERENATO
NOVITA IN TEMA DI CARCINOMA GASTRICO ROSA BERENATO ONCOLOGIA MEDICA 1 FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI MILANO PROGRESS AGAINST METASTATIC GC OS in first-line palliative setting Little progress
More informationNew Data from Ongoing Melanoma Study and Clinical Development Strategy Update
New Data from Ongoing Melanoma Study and Clinical Development Strategy Update Webcast - 29 th / 30 th May 2018 (ASX: IMM, NASDAQ: IMMP) Notice: Forward Looking Statements The purpose of the presentation
More informationHeat Biologics. Corporate Presentation March 9, 2018
Heat Biologics Corporate Presentation March 9, 2018 Forward Looking Statements This presentation includes statements that are, or may be deemed, forward-looking statements within the meaning of the Private
More informationMOLOGEN AG. Pioneering Immune Therapy. Annual Results Analysts Call March 25, 2014
Pioneering Immune Therapy Annual Results 2013 Analysts Call March 25, 2014 Disclaimer Certain statements in this presentation contain formulations or terms referring to the future or future developments,
More information